BeiGene Ltd (BEIGF)
12.58
0.00 (0.00%)
USD |
OTCM |
Jun 20, 16:00
BeiGene Revenue (Quarterly): 751.65M for March 31, 2024
Revenue (Quarterly) Chart
Historical Revenue (Quarterly) Data
Date | Value |
---|---|
March 31, 2024 | 751.65M |
December 31, 2023 | 634.41M |
September 30, 2023 | 781.31M |
June 30, 2023 | 595.26M |
March 31, 2023 | 447.80M |
December 31, 2022 | 380.10M |
September 30, 2022 | 387.63M |
June 30, 2022 | 341.57M |
March 31, 2022 | 306.63M |
December 31, 2021 | 213.98M |
September 30, 2021 | 206.44M |
June 30, 2021 | 149.99M |
March 31, 2021 | 605.87M |
December 31, 2020 | 100.10M |
September 30, 2020 | 91.08M |
June 30, 2020 | 65.64M |
March 31, 2020 | 52.06M |
December 31, 2019 | 56.89M |
September 30, 2019 | 50.14M |
June 30, 2019 | 243.35M |
Date | Value |
---|---|
March 31, 2019 | 77.83M |
December 31, 2018 | 58.67M |
September 30, 2018 | 54.20M |
June 30, 2018 | 52.80M |
March 31, 2018 | 32.54M |
December 31, 2017 | 18.17M |
September 30, 2017 | 220.21M |
June 30, 2017 | |
March 31, 2017 | |
December 31, 2016 | |
September 30, 2016 | |
June 30, 2016 | 0.393M |
March 31, 2016 | 0.677M |
December 31, 2015 | 4.677M |
September 30, 2015 | 1.38M |
June 30, 2015 | 1.38M |
March 31, 2015 | 1.379M |
December 31, 2014 | 1.381M |
September 30, 2014 | 6.496M |
Revenues Definition
Revenues measure the total amount of value that a company brings in during a certain period. This is also considered the "top-line" of the income statement. Revenues are used for all operating expenses as well as other line items which eventually lead to the net income for the company. Revenue is an extremely important metric when analyzing a company. A company with efficient margins is able to turn revenues into the most net income.
Revenue (Quarterly) Range, Past 5 Years
50.14M
Minimum
Sep 2019
781.31M
Maximum
Sep 2023
323.09M
Average
274.99M
Median
Revenue (Quarterly) Benchmarks
Theravance Biopharma Inc | 14.50M |
LumiraDx Ltd | 21.00M |
CEL-SCI Corp | -- |
AIM ImmunoTech Inc | 0.04M |
Revenue (Quarterly) Related Metrics
Net Income (Quarterly) | -251.15M |
Total Expenses (Quarterly) | 1.013B |
EPS Diluted (Quarterly) | -0.19 |
Enterprise Value | 15.46B |
Gross Profit Margin (Quarterly) | 83.38% |
Profit Margin (Quarterly) | -33.41% |
Earnings Yield | -4.69% |
Normalized Earnings Yield | -4.69 |